VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NVCR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NVCRNovocure Ltd
$11.14$1.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. NVCR
  4. Financial Ratios

Novocure Ltd (NVCR) Financial Ratios

Latest Ratios: P/E Ratio -10.7x · EV/EBITDA N/A · ROE -38.9%. (2013–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

NVCR Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$1.3B$1.4B$3.2B$1.6B$7.7B$7.8B$18.8B$8.2B$3.1B$1.8B$672M
Enterprise Value$1.5B$1.6B$3.7B$1.9B$8.1B$8.1B$19.0B$8.2B$3.1B$1.8B$668M
P/E Ratio →-10.69—————961.33————
P/S Ratio1.782.205.313.1214.2714.5138.1123.3212.3910.108.10
P/B Ratio3.654.238.924.3817.4018.9239.5437.6227.3915.754.72
P/FCF————814.09132.55223.81507.85———
P/OCF————249.3593.84190.02307.82———

P/E links to full P/E history page with 30-year chart

NVCR EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—2.486.173.8215.1515.2138.5223.2912.4310.218.06
EV / EBITDA——————481.521084.41———
EV / EBIT——————533.701620.39———
EV / FCF————863.82138.91226.24507.16———

NVCR Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin74.5%74.5%77.3%74.8%78.6%78.5%78.5%74.8%67.7%68.6%44.2%
Operating Margin-23.5%-23.5%-28.2%-45.7%-16.6%-8.3%6.1%-0.3%-13.6%-22.2%-139.1%
Net Profit Margin-20.8%-20.8%-27.9%-40.6%-17.2%-10.9%4.0%-2.1%-25.6%-34.8%-159.1%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-38.9%-38.9%-46.7%-51.5%-21.7%-13.2%5.7%-4.4%-56.3%-48.2%-67.1%
ROA-13.3%-13.3%-14.1%-17.7%-7.9%-5.3%2.6%-1.8%-21.0%-22.5%-44.7%
ROIC-16.4%-16.4%-16.0%-21.5%-7.9%-4.5%5.1%-0.4%-19.9%-21.8%-59.0%
ROCE-28.9%-28.9%-23.5%-23.3%-8.8%-4.6%4.6%-0.3%-13.7%-17.1%-44.0%

NVCR Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.850.851.901.641.321.420.950.771.330.860.68
Debt / EBITDA——————11.3922.29———
Net Debt / Equity—0.551.440.981.060.910.43-0.050.080.17-0.02
Net Debt / EBITDA——————5.17-1.49———
Debt / FCF————49.736.352.43-0.70———
Interest Coverage——-10.36-38.41-9.68-5.501.980.34-1.92-3.15-16.55

NVCR Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio2.902.901.465.787.007.538.805.104.984.887.10
Quick Ratio2.712.711.425.566.827.368.564.824.634.446.41
Cash Ratio2.052.051.275.086.116.587.523.803.813.655.96
Asset Turnover—0.810.490.440.450.470.470.730.730.670.29
Inventory Turnover4.064.063.913.363.914.703.883.743.552.521.81
Days Sales Outstanding—64.2461.5655.2671.9566.4574.1866.4553.7460.9627.91

NVCR Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield——————0.1%————
FCF Yield————0.1%0.8%0.4%0.2%———
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$111M$108M$106M$105M$103M$109M$97M$92M$89M$86M

Key Metrics

Growth RegimeExpanding
ProfitabilityStrained
Balance SheetAdequate
Cash FlowImproving
Top Statement Risk

Persistent operating losses and refinancing dependence

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiples Against Persistent Losses

Based on NVCR's reported figures, the price-to-sales multiple of 2.35 and price-to-book of 4.35 sit above typical medtech levels, while the negative trailing P/E of -10.89 leaves earnings-based valuation unusable and shifts the case toward revenue growth durability.

With no positive trailing earnings, the market appears to be pricing NVCR on revenue trajectory and the expected commercial ramp of TTFields rather than current profitability. A price-to-book of 4.35 against accumulated deficits of roughly -$1.4B suggests the market is valuing pipeline and intangible optionality well beyond tangible equity. Investors should monitor whether the 15.7% year-over-year revenue growth in the latest quarter can sustain a multiple that current earnings do not support.

Gross Margin Strength Obscured by Operating Losses

According to reported financial statements, NVCR's gross margin held near 77.0% in 3Q26 across a band of 73.2% to 79.2%, yet operating margin of -3.2% and net margin of -5.4% indicate the high-margin disposable model has not yet absorbed the R&D and SG&A base.

The stability of gross margin points to intact unit economics on the disposable transducer array model, the strongest structural feature in the ratio set. The gap between gross and operating margin reflects a fixed cost base sized for clinical expansion rather than current GBM revenue. Operating margin improved from -39.3% in 4Q24 to -3.2% in 3Q26, which may indicate growing operating leverage, but the absence of any positive operating quarter means earning power remains unproven.

Returns Recovering From Deep Negative Levels

Based on reported figures, ROIC improved from -10.2% in 1Q26 to -1.0% in 3Q26 and ROE moved from -21.2% to -3.0% over the same span, showing directional recovery from deeply negative returns but no positive capital compounding yet.

The trajectory suggests returns are converging toward breakeven as operating losses narrow rather than decaying further. Because ROE and ROIC remain negative, the company is still consuming rather than compounding invested capital. The improvement appears driven primarily by margin recovery rather than asset efficiency, since asset turnover has stayed in a tight range near 0.22 to 0.24, so sustained positive returns would depend on continued margin expansion.

Deleveraging Reduces Refinancing Pressure

As reported in financial statements, NVCR's debt-to-equity ratio fell from 2.34 in 3Q25 to 0.66 in 3Q26 as total debt declined to about $231.6M, though interest coverage remains negative and cannot yet confirm that debt service has become comfortable.

The sharp reduction in debt lowers the balance sheet risk that dominated the prior year, and the current debt-to-equity of 0.66 is more manageable than earlier readings. However, negative interest coverage means earnings do not currently cover interest expense, so the comfort of the leverage position depends on the cash balance rather than operating income. The deleveraging also coincided with cash that did not rise commensurately, which warrants further investigation into how repayment was financed.

Deleveraging May Mask Cash Dependence

Based on reported figures, the debt-to-EBITDA ratio is unavailable because EBITDA is negative, so the most commonly cited leverage metric cannot be used here and investors may instead rely on a misleading headline debt-to-equity improvement.

Debt-to-EBITDA is frequently applied to medtech issuers to gauge repayment capacity, but with operating income negative it yields no meaningful reading and obscures the true dependence on cash reserves and external funding. The headline fall in debt-to-equity from 2.34 to 0.66 may suggest durable balance sheet repair, yet it does not demonstrate that repayment came from operating cash generation. A more useful adjustment would be to track net cash burn against cash on hand and the timing of any refinancing, which warrants monitoring given the unexplained cash gap.

Download Financial Ratios Data

Includes 30+ ratios · 13 years · Updated daily

Consensus & Technical Research Suite
Open NVCR Terminal

NVCR Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

NVCR — Frequently Asked Questions

Quick answers to the most common questions about buying NVCR stock.

What is Novocure Ltd's P/E ratio?

Novocure Ltd's current P/E ratio is -10.7x. This places it at the 50th percentile of its historical range.

What is Novocure Ltd's ROE?

Novocure Ltd's return on equity (ROE) is -38.9%. The historical average is -39.3%.

Is NVCR stock overvalued?

Based on historical data, Novocure Ltd is trading at a P/E of -10.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Novocure Ltd's profit margins?

Novocure Ltd has 74.5% gross margin and -23.5% operating margin.